Iloprost

Generic Name: Iloprost

Brand Names: Ventavis

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₂O_₄

CAS Number: 78919-13-8

Unique Ingredient Identifier: JED5K35YGL

Background: Iloprost is a synthetic analogue of prostacyclin PGI2 that dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH).

Indication: Used for the treatment of pulmonary arterial hypertension.

Associated Conditions: NYHA class III Pulmonary arterial hypertension, NYHA class IV Pulmonary arterial hypertension

Associated Therapies: -

Clinical Trials

Infusion of Prostacyclin Vs Placebo for 72-hours in Mechanically Ventilated Patients with Acute Respiratory Failure

Phase 2

Recruiting

Conditions: Acute Respiratory Failure
Endothelial Dysfunction
Pulmonary Infection

Interventions: Drug: Isotonic saline
Drug: Iloprost

First Posted Date: 2024-03-20

Last Posted Date: 2024-11-13

Lead Sponsor: Pär Johansson

Target Recruit Count: 450

Registration Number: NCT06319274

Locations: 🇩🇰
Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark
🇩🇰
Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark
🇩🇰
Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital, Hillerød, Denmark

and more 1 locations

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Phase 2

Withdrawn

Conditions: Chronic Obstructive Pulmonary Disease
Lung Carcinoma
Bronchial Epithelial Dysplasia
Stage I Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Tobacco-Related Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bronchial Brush Biopsy
Procedure: Bronchoscopy
Drug: Placebo Administration
Drug: Iloprost
Other: Questionnaire Administration

First Posted Date: 2022-06-09

Last Posted Date: 2024-05-17

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05411107

Effect of Intraoperative Iloprost Inhalant on Hemodynamic Stability in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery

Not Applicable

Conditions: Coronary Artery Occlusive Disease

Interventions: Drug: Control (Normal saline)
Drug: Iloprost

First Posted Date: 2020-10-22

Last Posted Date: 2020-11-05

Lead Sponsor: Yonsei University

Target Recruit Count: 100

Registration Number: NCT04598191

Locations: 🇰🇷
Yonsei Severance Hospital, Seoul, Korea, Republic of

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure

Phase 2

Completed

Conditions: COVID-19
Respiratory Failure

Interventions: Drug: Isotonic saline
Drug: Iloprost

First Posted Date: 2020-06-09

Last Posted Date: 2024-05-07

Lead Sponsor: Pär Johansson

Target Recruit Count: 80

Registration Number: NCT04420741

Locations: 🇩🇰
Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark
🇩🇰
Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
🇩🇰
Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark

and more 2 locations

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure

Phase 2

Completed

Conditions: Septic Shock

Interventions: Drug: Isotonic saline
Drug: Iloprost

First Posted Date: 2019-10-11

Last Posted Date: 2024-05-07

Lead Sponsor: Jakob Stensballe, MD, PhD

Target Recruit Count: 279

Registration Number: NCT04123444

Locations: 🇩🇰
Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital, Hillerød, Denmark
🇩🇰
Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
🇩🇰
Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark

and more 3 locations

Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure

Phase 2

Completed

Conditions: Multi Organ Failure

Interventions: Drug: Iloprost
Drug: Isotonic saline

First Posted Date: 2019-04-04

Last Posted Date: 2024-05-08

Lead Sponsor: Pär Johansson

Target Recruit Count: 228

Registration Number: NCT03903939

Locations: 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Rigshospitalet (University of Copenhagen), Copenhagen, Denmark
🇩🇰
Aarhus University Hospital, Aarhus, Denmark

and more 2 locations

ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO)

Phase 3

Completed

Conditions: Septic Shock Hyperdynamic

Interventions: Drug: NaCl
Drug: ILOPROST

First Posted Date: 2018-12-28

Last Posted Date: 2024-07-03

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 240

Registration Number: NCT03788837

Locations: 🇫🇷
Departement of Anesthesiology, Critical Care and Burn Unit; Saint-Louis hospital, Paris, France

Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction

Phase 4

Conditions: Heart Failure With Normal Ejection Fraction

Interventions: Drug: Placebo
Drug: Iloprost

First Posted Date: 2018-08-08

Last Posted Date: 2019-08-14

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 34

Registration Number: NCT03620526

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension

Not Applicable

Completed

Conditions: Pulmonary Hypertension
Pulmonary Arterial Hypertension

Interventions: Drug: Iloprost

First Posted Date: 2017-12-07

Last Posted Date: 2018-10-26

Lead Sponsor: University of Giessen

Target Recruit Count: 30

Registration Number: NCT03365479

Locations: 🇩🇪
University Clinic Giessen and Marburg, Giessen, Hesse, Germany
🇩🇪
Kerckhoff-Klinik, Bad Nauheim, Germany

Iloprost in Acute Respiratory Distress Syndrome

Phase 3

Completed

Conditions: Respiratory Distress Syndrome, Adult

Interventions: Drug: Iloprost
Drug: control

First Posted Date: 2017-04-12

Last Posted Date: 2021-12-30

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 150

Registration Number: NCT03111212

Locations: 🇩🇪
University Hospital Tuebingen, Tuebingen, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy